Compare BEAM & BOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEAM | BOH |
|---|---|---|
| Founded | 2017 | 1897 |
| Country | United States | United States |
| Employees | N/A | 1877 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2019 | N/A |
| Metric | BEAM | BOH |
|---|---|---|
| Price | $24.53 | $74.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 5 |
| Target Price | $52.21 | ★ $81.80 |
| AVG Volume (30 Days) | ★ 1.8M | 317.9K |
| Earning Date | 05-05-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 3.74% |
| EPS Growth | ★ 82.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,000.00 | N/A |
| Revenue This Year | N/A | $15.66 |
| Revenue Next Year | $39.64 | $7.82 |
| P/E Ratio | ★ N/A | $17.08 |
| Revenue Growth | ★ 33.33 | N/A |
| 52 Week Low | $13.53 | $57.45 |
| 52 Week High | $36.44 | $80.61 |
| Indicator | BEAM | BOH |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 53.39 |
| Support Level | $23.42 | $69.76 |
| Resistance Level | $25.69 | $78.25 |
| Average True Range (ATR) | 1.32 | 1.50 |
| MACD | 0.04 | 0.31 |
| Stochastic Oscillator | 59.52 | 85.98 |
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.